5-Amino-1MQ tracker
Educational reference for 5-Amino-1MQ. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
—
Tmax
—
Category
other
Also known as: 5-amino-1-methylquinolinium
> PLACEHOLDER — pending clinical review by licensed pharmacist. 5-Amino-1MQ is a research NNMT inhibitor explored for metabolism and fat loss. Not well characterized in humans; not FDA-approved. Taken orally.
Mechanism
A small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). In preclinical research, inhibiting NNMT is associated with changes in NAD+ salvage and cellular metabolism in adipose tissue. Human mechanistic data are limited.
Research summary
Evidence is largely preclinical (cell and rodent studies) exploring metabolic and adipose-tissue effects. It is not an FDA-approved drug, and rigorous human clinical trial data are lacking. Claims should be read against that evidence gap.
Dosing in the literature
There is no established human clinical regimen and human pharmacokinetics are not well characterized. This summary does not provide dosing.
Reported side effects
Because controlled human safety data are limited, the side-effect and long-term safety profile is largely unknown. Sourcing and purity are common quality concerns raised in the literature.
Stacking notes
Discussed in metabolic-research contexts, sometimes alongside NAD+ precursors, but there is no controlled human evidence supporting specific combinations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- NNMT inhibition and metabolic regulation (preclinical review) · peer-reviewed review article (2018)predominantly animal-model evidence; search PubMed for NNMT inhibitor
- Regulatory status note · FDA / regulatory guidance (2024)not an approved drug; verify current status
Track 5-Amino-1MQ in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.